Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Capital Expenditures (2016 - 2026)

Ocular Therapeutix has reported Capital Expenditures over the past 14 years, most recently at $1.3 million for Q1 2026.

  • For Q1 2026, Capital Expenditures fell 31.35% year-over-year to $1.3 million; the TTM value through Mar 2026 reached $568000.0, down 68.43%, while the annual FY2025 figure was $1.2 million, 870.25% up from the prior year.
  • Capital Expenditures for Q1 2026 was $1.3 million at Ocular Therapeutix, up from -$8.0 million in the prior quarter.
  • Over five years, Capital Expenditures peaked at $6.0 million in Q3 2025 and troughed at -$8.0 million in Q4 2025.
  • A 5-year average of $373705.9 and a median of $276000.0 in 2022 define the central range for Capital Expenditures.
  • Biggest five-year swings in Capital Expenditures: surged 15335.48% in 2023 and later tumbled 17871.11% in 2025.
  • Year by year, Capital Expenditures stood at $3.2 million in 2022, then plummeted by 273.32% to -$5.6 million in 2023, then soared by 100.8% to $45000.0 in 2024, then tumbled by 17871.11% to -$8.0 million in 2025, then skyrocketed by 116.59% to $1.3 million in 2026.
  • Business Quant data shows Capital Expenditures for OCUL at $1.3 million in Q1 2026, -$8.0 million in Q4 2025, and $6.0 million in Q3 2025.